WorstPills.org - Search Results for dexfenfluramine (REDUX)

An expert, independent second opinion on more than 1,800 prescription drugs, over-the-counter medications, and supplements

Search Type: drug or dietary supplement name
Search Term: dexfenfluramine (REDUX)

Drug Profiles \| Worst Pills, Best Pills Newsletter Articles \| Additional Information from Public Citizen

Drug and Dietary Supplement Profiles

A comprehensive review of the safety and effectiveness of this drug. If the drug is not a Do Not Use product, information on adverse effects, drug interactions and how to use the medication are included.

Search results below include drug profiles where your selected drug is a secondary subject of discussion

benzphetamine (DIDREX); diethylpropion (DURAD, TENUATE, TEPANIL); phendimetrazine (PLEGINE); phentermine (ADIPEX-P, ATTI PLEX P, FASTIN, IONAMIN, KRAFTOBESE, PANSHAPE M, PHENTERCOT, PHENTRIDE, PRO-FAST, RAPHTRE, SUPRAMINE, TARA-8, TERAMINE, TERMENE)
We list these drugs as Do Not Use drugs because they cause only very limited weight loss, are addictive and can cause central nervous system stimulation and high blood pressure.

Worst Pills, Best Pills Newsletter Articles

Search results below include Worst Pills, Best Pills Newsletter Articles where your selected drug is a secondary subject of discussion

Lorcaserin (BELVIQ): Another Do Not Use Diet Drug [hide all summaries]
(March 2017)
Learn about the unacceptable dangers posed by lorcaserin, a diet drug that was approved by the FDA in 2012 and that has similarities to the previously banned diet drug fenfluramine.
VYVANSE for Binge Eating: Old Pill, New ‘Disease’ [hide all summaries]
(September 2015)
Don't fall prey to a drug company's slick marketing campaign of a dangerous drug recently approved by the FDA for treatment of a newly designated disease called "binge eating disorder."
When EMA and FDA Decisions Conflict: Differences in Patients or in Regulation? [hide all summaries]
(December 2013)
Are Americans more resistant to the risks and more likely to benefit from certain drugs than Europeans? Or is the European Medicines Agency (EMA) more resistant than the U.S. Food and Drug Administration (FDA) to the drug industry’s desire to get approval for drugs with unique risks but without compensating benefits? This article discusses two recently FDA-approved diet drugs deemed too unsafe for Europeans.
Troubling New Drug Approvals in 2012 [hide all summaries]
(March 2013)
Find out which drugs approved in 2012 have risks greatly exceeding their benefits or no meaningful benefits. If you are using any of the DO NOT USE drugs reviewed in the article, talk to your doctor before stopping their use.
Inadvertent Adverse Reactions With Commonly Used Drugs [hide all summaries]
(January 2012)
Find out how to prevent emergency hospitalizations from two commonly used drugs, warfarin (COUMADIN) and clopidogrel (PLAVIX). There are approximately 33,000 emergency hospitalizations a year from warfarin alone. This article includes a list of more than 50 drugs that can have harmful interactions with warfarin and/or clopidogrel.
Blockbuster Arthritis Drug Rofecoxib (VIOXX) Withdrawn From Market [hide all summaries]
(November 2004)
Vioxx is the ninth prescription drug to be taken off the market in the past seven years that Worst Pills, Best Pills News readers were previously warned DO NOT USE. The average time between warning readers not to use these drugs and their removal from the market was one year and eight months.
New Warning! Heart Valve Damage With the Parkinson’s Disease Drug Pergolide (PERMAX) [hide all summaries]
(April 2003)
On February 24, 2003, Eli Lilly and Company of Indianapolis informed healthcare professionals that the professional product labeling, or “package insert,” for pergolide (PERMAX) was being updated to include a warning about the possibility of heart valve damage with the drug.

Additional Information from Public Citizen

Search results below include Additional Information from Public Citizen where your selected drug is a secondary subject of discussion

Weight Loss Drug Rimonabant Can Cause Serious Physical and Psychological Harm and Birth Defects, Public Citizen Tells FDA [hide all summaries]
The Food and Drug Administration (FDA) should not approve the new diet drug rimonabant (marketed as Acomplia in Europe and known as Zimulti in the U.S.) because it produces only modest weight loss and has been shown to produce serious physical and psychological adverse effects, according to Public Citizen testimony before an FDA advisory committee meeting today.
Comments on: The Prescription Drug User Fee Act (PDUFA) (HRG Publication #1606) [hide all summaries]
Public Citizen=s position was then, and remains, that Congress must adequately fund the FDA using public money. Also, PDUFA=s second re-authorization in 1997, with its slavish deadlines and the accompanying ill-advised Food and Drug Administration Modernization Act (FDAMA) are examples of failed experiments in public policy.

SHOW primary search results for dexfenfluramine (REDUX)